ImmunityBio reported a quarterly loss of $0.09 per share, missing the Zacks consensus estimate for a $0.08 loss. The result was still an improvement from a $0.15 per-share loss in the year-ago quarter. Overall, the release is a modest earnings miss with year-over-year loss narrowing, likely a limited stock-specific move.
ImmunityBio reported a quarterly loss of $0.09 per share, missing the Zacks consensus estimate for a $0.08 loss. The result was still an improvement from a $0.15 per-share loss in the year-ago quarter. Overall, the release is a modest earnings miss with year-over-year loss narrowing, likely a limited stock-specific move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
